FIELD: medicine.
SUBSTANCE: invention refers to new compounds with pharmacological activity to sigma-receptor, and more specifically to pyrazole derivatives of formula (I) in which radicals and symbols have the values defined in cl. 1 of the patent claim; to a method for preparing such compounds; to a pharmaceutical composition containing them and to their application for manufacturing a medicinal agent for treatment and prevention of a sigma-receptor mediated disease or a condition, particularly for treatment of psychotic illness, such as depression, anxiety or schizophrenia, and neuropathic or inflammatory pain, including allodynia and/or hyperalgesia.
EFFECT: improved clinical effectiveness.
11 cl, 2 dwg, 1 tbl, 112 ex
Title | Year | Author | Number |
---|---|---|---|
SIGMA-LIGANDS FOR APPLICATION IN PREVENTION AND/OR TREATMENT OF POSTOPERATIVE PAIN | 2011 |
|
RU2569055C2 |
SUBSTITUTED PYRAZOLES | 2001 |
|
RU2286343C2 |
METHOD FOR TREATMENT OF ALLERGY BY USING SUBSTITUTED PYRAZOLES | 2001 |
|
RU2290179C2 |
METHOD FOR TREATMENT OF ALLERGY BY USING SUBSTITUTED PYRAZOLES | 2001 |
|
RU2259202C2 |
JAK INHIBITOR COMPOUND AND USE THEREOF | 2020 |
|
RU2820445C2 |
NOVEL PYRAZOLE DERIVATIVES | 2022 |
|
RU2816835C1 |
METHOD FOR TREATMENT ALLERGY BY USING SUBSTITUTED PYRAZOLES | 2001 |
|
RU2277909C2 |
BICYCLIC LACTAMS AND METHODS FOR USE THEREOF | 2016 |
|
RU2716136C2 |
BICYCLIC TETRAHYDROPYRAZOLEPYRIDINES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, PHARMACEUTICAL COMPOSITION, METHOD OF PHOSPHODIESTERASE INHIBITION, METHOD OF PATIENT TREATMENT | 1994 |
|
RU2131876C1 |
SIGMA-RECEPTOR INHIBITORS | 2005 |
|
RU2417987C2 |
Authors
Dates
2010-11-27—Published
2005-08-29—Filed